title: Current treatments of neuroendocrine tumors role of biotherapy and chemotherapy.
abstract: Neuroendocrine tumors are rare neoplasms originating from cells belonging to a diffuse or confined neuroendocrine system and characterized by a significant histopatologic and biologic heterogeneity. Timely diagnosis is delayed because they are often clinically silent for their low differentiation grade and the absence of any symptom due to abnormal hormone release. For these reasons, many neuroendocrine tumor patients are not treated medically for metastatic or inoperable disease. Medical treatments include biotherapy, with interferon-alpha and somatostatin analogues, and chemotherapy. Somastostatin analogues are widely used in patients with symptoms and with carcinoids of low differentiation grade. Interferon-alpha is used alone or in combination with somatostatin analogues. Chemotherapy is active in patients with poorly differentiated neuroendocrine tumors. The therapeutic regimen commonly used is the combination of cisplatinum and etoposide. In conclusion, no standard treatment for NET has yet been identified, and the response criteria suggested by ITMO remain a reference point. The clinical aspect of the disease and biologic features suggest the identification of neuroendocrine tumors patients suitable for the appropriate therapies. On these bases, it is recommended that diagnosis and treatment of neuroendocrine tumors be carried out at specialized oncological centers involved in clinical trials.
authors.affiliation: Medical Oncology Unit B, National Cancer Institute, Milan, Italy.
authors.forename: Silvia
authors.initials: S
authors.lastname: Della Torre
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Procopio
authors.forename: Alberto
authors.initials: A
authors.lastname: Fusi
authors.forename: Laura
authors.initials: L
authors.lastname: Catena
authors.forename: Leonardo
authors.initials: L
authors.lastname: Ferrari
authors.forename: Paola
authors.initials: P
authors.lastname: Nova
authors.forename: Angela
authors.initials: A
authors.lastname: Denaro
authors.forename: Ettore
authors.initials: E
authors.lastname: Bichisao
authors.forename: Emilio
authors.initials: E
authors.lastname: Bajetta
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D018358:Neuroendocrine Tumors / Q000628:therapy*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D013004:Somatostatin